Poolbeg Pharma is rapidly carving out a space at the cutting edge of biotech innovation, with high-value therapeutic programmes and artificial intelligence-led drug discovery offering a compelling proposition for forward-thinking investors.
Poolbeg Pharma is a clinical-stage biopharmaceutical company developing novel treatments that address areas of significant unmet medical need. Its strategic focus spans life-changing treatments for cytokine release syndrome (CRS) associated with cancer immunotherapy and a next-generation, orally delivered GLP-1 therapy targeting metabolic diseases like obesity. These are multi-billion-pound markets with growing demand for safer, more effective solutions.
The company’s strength lies not only in its scientific ambitions but also in its execution. Its leadership team combines deep expertise and a proven track record in bringing pharmaceutical innovations to market. That experience is being channelled into advancing programmes with strong commercial potential.
What further sets Poolbeg apart is its pioneering use of artificial intelligence to drive discovery. By drawing on two decades of human challenge trial data, Poolbeg’s AI engine accelerates the identification of promising drug targets and candidates. This approach aims to reduce costs, shorten timelines, and raise the probability of clinical and commercial success—critical advantages in today’s competitive biotech landscape.
Poolbeg Pharma is dedicated to delivering impactful medical innovations with a de-risked and efficient development model that creates tangible value for investors and patients alike.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
